PHARMACOLOGICAL ACTIONColofac 135 mg is a musculotropic spasmolytic agent with a selective action, especially on smooth muscle spasms of the gastro-intestinal tract.
In vivo studies showed Colofac 135 mg to have spasmolytic properties, especially on the sphincter of Oddi (20-40 times greater than with papaverine), on the cardia and on the ileum. Little or no antispasmodic effect was seen on the uterus and the bronchial muscles.
Gastric emptying time and intestinal propulsion were affected much less than by papaverine. No significant inhibition of normal peristalsis has been observed.

DOSAGE AND DIRECTIONS FOR USE135 mg mebeverine hydrochloride (1 tablet) 3 times daily, preferably before meals. After a period of a few weeks when the desired effect has been obtained, the dosage may be gradually reduced.
As atropine-like effects are absent, Colofac 135 mg is not contra-indicated in patients with glaucoma or prostatic hypertrophy.

SIDE-EFFECTS AND SPECIAL PRECAUTIONSAfter the administration of Colofac 135 mg cases of depression, headache, dizziness, diarrhoea and constipation (most probably not attributable to the medicine) were reported.The safety of Colofac 135 mg in pregnancy has not been established.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENTNone known.

IDENTIFICATIONWhite, round sugar-coated tablets.

PRESENTATIONPacks of 20 and 100 tablets.

STORAGE INSTRUCTIONSStore in a dry, dark place, at temperatures not exceeding 30°C. Keep out of reach of children.